Dr. Shallis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 York St
New Haven, CT 06510Phone+1 203-688-4242Fax+1 203-785-4116
Education & Training
Rutgers Robert Wood Johnson Medical SchoolClass of 2014
Certifications & Licensure
CT State Medical License 2017 - 2025
RI State Medical License 2014 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm Start of enrollment: 2023 Jun 27
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leuke...Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis
American Journal of Hematology. 2024-12-01 - Cost-effectiveness of Enasidenib versus conventional care for older patients withmutant refractory/relapsed AML.Abdulrahman Alhajahjeh, Kishan K Patel, Rory M Shallis, Nikolai A Podoltsev, Tariq Kewan
Leukemia & Lymphoma. 2024-11-19 - Outcomes of patients with acute myeloid leukemia treated with intensive therapy after failure of venetoclax-inclusive, less-intensive therapy.Rohan K Achar, Benjamin J McCormick, Emily Dworkin, Emily M Geramita, Annie Im
Leukemia Research. 2024-11-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
